179 related articles for article (PubMed ID: 21901297)
41. Switching from methadone to tapentadol for cancer pain.
Mercadante S; Ferrera P; Adile C
J Pain Symptom Manage; 2012 Sep; 44(3):e3-5. PubMed ID: 22819437
[No Abstract] [Full Text] [Related]
42. Clarifications on oxycodone-naloxone combination in cancer pain management.
Mercadante S
Support Care Cancer; 2012 Jul; 20(7):1351-2. PubMed ID: 22526146
[No Abstract] [Full Text] [Related]
43. Conversion from parenteral to oral methadone.
González-Barboteo J; Porta-Sales J; Sánchez D; Tuca A; Gómez-Batiste X
J Pain Palliat Care Pharmacother; 2008; 22(3):200-5. PubMed ID: 19042849
[TBL] [Abstract][Full Text] [Related]
44. Controlled-release oxycodone and morphine in cancer related pain.
Heiskanen T; Kalso E
Pain; 1997 Oct; 73(1):37-45. PubMed ID: 9414055
[TBL] [Abstract][Full Text] [Related]
45. Switching from methadone to a different opioid: what is the equianalgesic dose ratio?
Walker PW; Palla S; Pei BL; Kaur G; Zhang K; Hanohano J; Munsell M; Bruera E
J Palliat Med; 2008 Oct; 11(8):1103-8. PubMed ID: 18980450
[TBL] [Abstract][Full Text] [Related]
46. Fentanyl tolerance in the treatment of cancer pain: a case of successful opioid switching from fentanyl to oxycodone at a reduced equivalent dose.
Sutou I; Nakatani T; Hashimoto T; Saito Y
J Pain Palliat Care Pharmacother; 2015 Jun; 29(2):161-5. PubMed ID: 26095488
[TBL] [Abstract][Full Text] [Related]
47. Therapy switching in patients receiving long-acting opioids.
Berger A; Hoffman DL; Goodman S; Delea TE; Seifeldin R; Oster G
Ann Pharmacother; 2004 Mar; 38(3):389-95. PubMed ID: 14742831
[TBL] [Abstract][Full Text] [Related]
48. Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home.
Mercadante S; Casuccio A; Agnello A; Serretta R; Calderone L; Barresi L
J Clin Oncol; 1998 Nov; 16(11):3656-61. PubMed ID: 9817288
[TBL] [Abstract][Full Text] [Related]
49. Rotation to methadone after opioid dose escalation: How should individualization of dosing occur?
Zimmermann C; Seccareccia D; Booth CM; Cottrell W
J Pain Palliat Care Pharmacother; 2005; 19(2):25-31. PubMed ID: 16061458
[TBL] [Abstract][Full Text] [Related]
50. Opioid rotation from oral morphine to oral oxycodone in cancer patients with intolerable adverse effects: an open-label trial.
Narabayashi M; Saijo Y; Takenoshita S; Chida M; Shimoyama N; Miura T; Tani K; Nishimura K; Onozawa Y; Hosokawa T; Kamoto T; Tsushima T;
Jpn J Clin Oncol; 2008 Apr; 38(4):296-304. PubMed ID: 18326541
[TBL] [Abstract][Full Text] [Related]
51. Methadone in end-of-life pain management.
Chau DL; Mason MN
J Opioid Manag; 2005; 1(5):244-8. PubMed ID: 17319557
[No Abstract] [Full Text] [Related]
52. [Interindividual variation of pharmacokinetic disposition of and clinical responses to opioid analgesics in cancer pain patients].
Naito T; Kawakami J
Yakugaku Zasshi; 2015; 135(5):709-15. PubMed ID: 25948306
[TBL] [Abstract][Full Text] [Related]
53. The role of methadone in opioid rotation-a Polish experience.
Leppert W
Support Care Cancer; 2009 May; 17(5):607-12. PubMed ID: 19043743
[TBL] [Abstract][Full Text] [Related]
54. Strategies for the treatment of cancer pain in the new millennium.
Ripamonti C; Dickerson ED
Drugs; 2001; 61(7):955-77. PubMed ID: 11434451
[TBL] [Abstract][Full Text] [Related]
55. Methadone response in advanced cancer patients with pain followed at home.
Mercadante S; Casuccio A; Agnello A; Barresi L
J Pain Symptom Manage; 1999 Sep; 18(3):188-92. PubMed ID: 10517040
[TBL] [Abstract][Full Text] [Related]
56. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study.
Bruera E; Palmer JL; Bosnjak S; Rico MA; Moyano J; Sweeney C; Strasser F; Willey J; Bertolino M; Mathias C; Spruyt O; Fisch MJ
J Clin Oncol; 2004 Jan; 22(1):185-92. PubMed ID: 14701781
[TBL] [Abstract][Full Text] [Related]
57. Patient-controlled analgesia with oral methadone in cancer pain: preliminary report.
Mercadante S; Sapio M; Serretta R; Caligara M
Ann Oncol; 1996 Aug; 7(6):613-7. PubMed ID: 8879376
[TBL] [Abstract][Full Text] [Related]
58. Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone.
Ward A; Bozkaya D; Fleischmann J; Dubois D; Sabatowski R; Caro JJ
Curr Med Res Opin; 2007 Oct; 23(10):2333-45. PubMed ID: 17697453
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis.
Hale M; Tudor IC; Khanna S; Thipphawong J
Clin Ther; 2007 May; 29(5):874-888. PubMed ID: 17697906
[TBL] [Abstract][Full Text] [Related]
60. [Effect of vaginal administration of controlled-release oxycodone on cancer pain].
Zhang X; Ruan XJ; Liu C; Yu ZH
Ai Zheng; 2009 Jul; 28(7):740-2. PubMed ID: 19624902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
